Arbutus Biopharma Corporation · NASDAQ:ABUS
Arbutus Biopharma — Investor Presentation (September 2023)
25 slides from Arbutus Biopharma's investor presentation, Sep 11, 2023
Slide 1: Corporate Presentation
NASDAQ: ABUS www.arbutusbio.com September 11, 2023 Corporate Presentation © 2023 Arbutus Biopharma, Inc.
Slide 2: Forward-Looking Statements
Forward - Looking Statements This presentation contains forward - looking statements within the meaning of the U . S . Private Securities Litigation Reform Act of 1995 and Canadian securities laws . All statements that are not historical facts are hereby identified as forward - looking statements fo
Slide 3: Our Strategy for Value Creation
Our Strategy for Value Creation Leverage the proven track record of success established with our team's expertise in understanding and treating viral infections by discovering and developing a differentiated pipeline of therapies targeting chronic HBV. Develop a combination therapy that includes ant
Slide 4: Investment Highlights
Investment Highlights Strong financial position Indications with significant unmet medical need & large market opportunities Patented LNP technology Portfolio of internally discovered assets with distinct MOAs Lead HBV compound – imdusiran (AB - 729) RNAi therapeutic in multiple Phase 2a combination
Slide 5: Pipeline
Pipeline AB - 101 cHBV NA: Nucleoside Analogue 5 Imdusiran (AB - 729) cHBV Imdusiran (AB - 729) cHBV Imdusiran (AB - 729) cHBV AB - 729 - 201 Combo trial ( imdusiran + Peg - IFN α - 2a + NA) AB - 729 - 202 Combo trial ( imdusiran + vaccine + NA +/ - checkpoint inhibitor) AB - 729 - 001 single - asce
Slide 6: HBV Overview
HBV Overview Life - threatening liver infection caused by hepatitis B virus (HBV) Transmitted through body fluids and from mother to child Long - term chronic infection ( cHBV ) leads to higher risk of cirrhosis and/or liver cancer Cause & Symptoms Diagnosis HBsAg detection Additional biomarkers nec
Slide 7: HBV Presents a Significant Unmet Medical Need
Africa 60M E Mediterranean 21M SE Asia 39M W Pacific 115M EU 15M Americas 7M ~820k people die every year as a consequence despite the availability of effective vaccines and antivirals. people are chronically infected with HBV, globally. >290M >290M Chronic HBV Sources: https://www.who.int/news - roo
Slide 8: 3-Pronged Approach to Therapeutic Success
Suppress Reduce Boost Viral DNA and cccDNA Pool Viral Antigen - HBsAg Host Immune System Leading to an HBV Cure 3 - Pronged Approach to Therapeutic Success Therapeutic success will require a combination of agents with complementary MOAs. Suppress HBV DNA Reduce viral antigens Boost host immune respo
Slide 9: RNAi Therapeutic
RNAi Therapeutic Warbutus
Slide 10: Imdusiran RNAi Therapeutic with GalNAc delivery
Proprietary GalNAc - conjugate delivery technology provides liver targeting and enables subcutaneous dosing Single trigger RNAi agent targeting all HBV transcripts Inhibits HBV replication and lowers all HBV antigens Pan - genotypic activity across HBV genotypes Demonstrated complementarity with oth
Slide 11: 001: Phase 1a/1b Clinical Trial with Imdusiran
AB - 729 - 001: Phase 1a/1b Clinical Trial with Imdusiran HBeAg: HBV E antigen | TDF: tenofovir disoproxil fumarate Part 3: Multiple Ascending Dose in cHBV Patients E: 60mg Q4W HBV DNA - F: 60mg Q8W HBV DNA - G: 90mg Q8W + TDF HBV DNA+ I: 90mg Q8W HBV DNA - J: 90mg Q12W HBV DNA - K: 90mg Q8W HBV DNA
Slide 12: 001: Robust HBsAg Declines Irrespective of Dose, Schedule, Status
AB - 729 - 001: Robust HBsAg Declines Irrespective of Imdusiran Dose, Dosing Schedule, HBeAg or HBV DNA Status Mean (SE) Baseline and Δ log 10 HBsAg by Visit Data shown as mean (SE) log 10 IU/mL; minimum of 5 subjects/timepoint. Last imdusiran (AB - 729) dose Cohort E: Week 44, Cohorts F, I, G, K: W
Slide 13: 001: Robust & Sustained HBsAg Declines On- or Off-Treatment
Data presented at EASL 2022 and AASLD 2022 13 Change in HBsAg vs time AB - 729 - 001 : Robust & Sustained HBsAg Declines While On - or Off - Treatment with Imdusiran 33 of 41 patients had HBsAg < 100 IU/mL at some point during the trial 1 patient in Cohort E (baseline HBsAg = 583.5 IU/mL) who qualif
Slide 14: Imdusiran Shows Low Levels of HBV Biomarkers Off-Treatment
AB - 729 - 001 : Imdusiran Shows Low Levels of HBV Biomarkers Persisting in cHBV Patients While Off - Treatment 7 of 9 (78%) subjects remain off NA therapy for 44 - 64 weeks and all completed imdusiran treatment over 1½ years ago Most subjects have maintained low HBV DNA levels off treatment 14 Data
Slide 15: Treatment with Imdusiran Reactivates HBV Specific Immunity
AB - 729 - 001 : Treatment with Imdusiran Reactivates HBV Specific Immunity in Some Patients 15 0 4 812162024283236404448525660 0 1 2 3 4 5 0 20 40 60 H B s A g ( L o g 1 0 I U / m L ) Patient 43 60 mg Q4W 0 4 8 1216202428323640444852 0 1 2 3 4 0 10 20 30 40 50 60 H B s A g ( L o g 1 0 I U / m L ) P
Slide 16: Safety Summary
AB - 729 - 001 Safety Summary Imdusiran is generally safe and well - tolerated after repeat dosing for up to 48 weeks No treatment - related SAEs or discontinuations due to AEs No treatment - related Grade 3 or 4 AEs No treatment - related Grade 3 or 4 laboratory abnormalities • Grade 1 and Grade 2
Slide 17: Clinical Trial Key Takeaways
AB - 729 - 001 Clinical Trial Key Takeaways Imdusiran provided robust and comparable HBsAg declines regardless of dose, dosing interval, HBeAg or DNA status Discontinuation of both imdusiran and NA - therapy results in sustained reduction in HBsAg and HBV DNA in 7 of 9 patients Imdusiran was general
Slide 18: Phase 2a POC Clinical Trial: 201 with Peg-IFN
Phase 2a POC Clinical Trial Imdusiran in combination with ongoing NA therapy and short courses of Peg - IFN α - 2 a in cHBV patients AB - 729 - 201: Follow - up (24 - weeks) Imdusiran + NA + IFN (n=12) NA + IFN (n=12) Imdusiran +NA+IFN (n=8) NA + IFN (n=8) Imdusiran + NA (60mg Q8W) n=43 HBeAg - Rand
Slide 19: Phase 2a POC Clinical Trial: 202 with VTP-300
Phase 2a POC Clinical Trial POC Phase 2a clinical trial evaluating imdusiran in combination with Vaccitech’s immunotherapeutic, VTP - 300, with or without low dose nivolumab, and a NA AB - 729 - 202: Primary objective: evaluate safety and reactogenicity of imdusiran followed by VTP - 300 or placebo
Slide 20: Strategic Collaboration with Qilu Pharmaceutical
Strategic Collaboration Exclusive Licensing* and Strategic Partnership Develop, manufacture and commercialize imdusiran in mainland China, Hong Kong, Macau and Taiwan Imdusiran Upfront payment (received in 2022) $40M Equity investment (received in 2022) $15M Commercialization and milestone payments
Slide 21: Oral PD-L1 Inhibitor
Oral PD-L1 Inhibitor Warbutus
Slide 22: AB-101: Small-Molecule Oral PD-L1 Inhibitor for HBV
AB - 101: Small - Molecule Oral PD - L1 Inhibitor for HBV AB - 101 is highly potent with demonstrated activity against PD - L1 in cells from chronic HBV patients AB - 101 reduces PD - L1 on the surface of human primary myeloid cells AB - 101 reinvigorates HBV - specific cHBV patient T - cells Data p
Slide 23: AB-101: Oral PD-L1 Inhibitor for HBV Immune Reactivation
AB - 101: Oral PD - L1 Inhibitor for HBV Immune Reactivation PD - 1: Programmed death ligand protein | Abs: Antibodies Currently in a Phase 1a/1b clinical trial Rationale • HBV immune tolerance is a critical driver of cHBV infection • PD - 1:PD - L1 checkpoint axis plays a key role in immune toleriz
Slide 24: 2023 Key Milestones
2023 Key Milestones Cash balance * of $164M as of June 30, 2023, cash runway through Q3 2025; 2023 net cash burn of between $90M and $95M *Consists of cash, cash equivalents and marketable securities 24 Anticipated Timing 2023 Milestone 1H Imdusiran : Dose f irst patient in the imdusiran+VTP - 300+N
Slide 25: Thank You
Thank You © 2023 Arbutus Biopharma, Inc.
Arbutus Biopharma — Investor Presentation (September 2023) on 6ix